论文部分内容阅读
目的探究唑来膦酸联合希罗达治疗乳腺癌多发性骨转移的临床疗效、不良反应及预后。方法选取2016年1月~2017年1月收治的86例乳腺癌多发性骨转移患者临床资料,依据不同治疗方案分为对照组(43例)与研究组(43例),对照组行希罗达治疗,研究组行希罗达联合唑来膦酸治疗,比较治疗3个周期后两组骨转移灶疗效、不良反应与生存质量。结果研究组骨转移灶治疗总有效率(76.74%)高于对照组(55.81%),差异有统计学意义(P<0.05,P<0.01),研究组与对照组不良反应发生率的差异无统计学意义(P>0.05),研究组生存质量改善率(69.77%)较对照组(46.51%)高,差异有统计学意义(P<0.05)。结论乳腺癌多发性骨转移应用唑来膦酸及希罗达联合治疗可有效提高疗效,改善患者预后,且联合用药未显著增加不良反应,安全性较高,具推广及应用价值。
Objective To investigate the clinical efficacy, adverse reactions and prognosis of zoledronic acid combined with Xeloda in the treatment of multiple bone metastases of breast cancer. Methods The clinical data of 86 patients with multiple bone metastases from breast cancer who were admitted from January 2016 to January 2017 were divided into control group (43 cases) and study group (43 cases) according to different treatment regimens. The control group Up to treatment, the study group Xeloda combined with zoledronic acid treatment, the treatment of three cycles of bone metastases after treatment, adverse reactions and quality of life. Results The total effective rate of bone metastasis in study group was 76.74%, which was significantly higher than that in control group (55.81%) (P <0.05, P <0.01). There was no difference in adverse reactions between study group and control group (P> 0.05). The improvement rate of quality of life in the study group (69.77%) was higher than that in the control group (46.51%), the difference was statistically significant (P <0.05). Conclusion Multiple bone metastases of breast cancer with zoledronic acid and Xeloda combined treatment can effectively improve the efficacy and improve the prognosis of patients, and the combination did not significantly increase the adverse reactions, safety is high, with the promotion and application value.